Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(20%)

Results Posted

33%(1 trials)

Phase Distribution

Ph not_applicable

40%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 4Post-market surveillance

3(60.0%)

N/ANon-phased studies

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Other(1)

Detailed Status

Completed3

unknown1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 43 (60.0%)

N/A2 (40.0%)

Trials by Status

unknown120%

recruiting120%

completed360%

Recent Activity

1 active trials

Showing 5 of 5

completedphase_4

Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

NCT05774691

recruitingnot_applicable

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

NCT03140631

Clinical Trials (5)

Showing 5 of 5 trials

NCT05774691Phase 4

Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

Completed

NCT07477977Not Applicable

Dose for Reversal of Heparin After Cardiopulmonary Bypass

Recruiting

NCT02974660Phase 4

Protamine Sulfate During Transcatheter Aortic Valve Implantation

Completed

NCT03787641Not Applicable

Systematic Evaluation of Protamine Doze in Cardiac Surgery

Unknown

NCT03140631Phase 4

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5